Physician profile
Gebran Khneizer
NPI 1386039477
$2,811.43
in general payments reported to CMS, 2019-2025
27 companies · $614 in 2025
The $614 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $29.97 · 2022: $184 · 2023: $732 · 2024: $1,252 · 2025: $614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,399 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,398.51 |
| Education | $199.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $699.59 | 2023-2025 | |
| Janssen Biotech, INC. | $495.66 | 2022-2025 | Stelara, Tremfya |
| Intercept Pharmaceuticals, INC. | $403.16 | 2022-2025 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $171.14 | 2024 | Iqirvo |
| Mallinckrodt Hospital Products INC. | $162.69 | 2023 | Terlivaz |
| Gilead Sciences, INC. | $161.09 | 2024-2025 | Livdelzi |
| Lilly USA, LLC | $143.11 | 2024-2025 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $99.61 | 2023-2024 | Eohilia, Entyvio |
| Pfizer INC. | $77.23 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $64.77 | 2023-2024 | Dupixent |
| Merck Sharp & Dohme LLC | $42.14 | 2023-2024 | Zinplava, Dificid |
| Ironwood Pharmaceuticals, INC | $28.69 | 2023 | Linzess |
| Celgene Corporation | $27.49 | 2023-2024 | Zeposia |
| Cook Medical LLC | $26.79 | 2021-2023 | Cook |
| Genzyme Corporation | $26.38 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $20.61 | 2025 | Zenpep |
| Celltrion USA INC. | $19.81 | 2025 | Vegzelma |
| Biocon Biologics INC | $19.35 | 2023 | Hulio |
| Mauna Kea Technologies, INC. | $19.17 | 2024 | |
| Dynavax Technologies Corporation | $17.80 | 2021 | |
| Daiichi Sankyo INC. | $16.59 | 2024 | Injectafer |
| Ardelyx, INC. | $15.20 | 2025 | Ibsrela |
| Qol Medical, LLC | $14.83 | 2023 | Sucraid |
| Madrigal Pharmaceuticals | $14.73 | 2025 | Rezdiffra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.39 | 2024 | Cyltezo |
| Organon LLC | $9.41 | 2025 | Hadlima, Renflexis |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gebran Khneizer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.